107 results
Page 2 of 6
S-4
iy4e4 dybyfbihdyb
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-2.1
f94kxjme1t
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-2.1
n5eg1pe4njw 6hewo0
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFA14A
6k1cpy
16 Dec 22
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
heg8yuc 7mayw
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
PRRN14A
72b p27qia
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
DEFA14A
EX-99.1
3pbpzchwfhfvhimwhg
5 Dec 22
Additional proxy soliciting materials
9:59pm
8-K
EX-99.1
nask2i7yv7vko 2l
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
PRRN14A
c8gv5vmvpb7gm
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PREC14A
kjjewz
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
8-K
EX-99.1
cgyfxaqprm0
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
pu9gryt5drecresw
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
z3xr73yl4pjm65ctz4ko
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
l7ndwu
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
ea217z5913kh4ee
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
9oddq9
27 Jul 22
Other Events
7:30am
424B5
m47dfw z0k46zlme87h
22 Jul 22
Prospectus supplement for primary offering
4:15pm